SAGE Therapeutics (NASDAQ:SAGE) received a $170.00 target price from Oppenheimer in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 56.08% from the company’s current price.

A number of other brokerages have also recently issued reports on SAGE. BidaskClub cut SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday. Leerink Swann began coverage on SAGE Therapeutics in a report on Monday, November 12th. They issued an “underperform” rating and a $80.00 target price for the company. JPMorgan Chase & Co. set a $205.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 6th. Royal Bank of Canada upped their target price on SAGE Therapeutics from $259.00 to $261.00 and gave the stock an “outperform” rating in a report on Monday, November 5th. Finally, Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 1st. Two analysts have rated the stock with a sell rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. SAGE Therapeutics has an average rating of “Buy” and a consensus price target of $204.14.

Shares of NASDAQ:SAGE traded down $0.78 during trading on Tuesday, reaching $108.92. 9,619 shares of the company traded hands, compared to its average volume of 516,998. The company has a market cap of $5.35 billion, a price-to-earnings ratio of -15.27 and a beta of 2.76. SAGE Therapeutics has a 52 week low of $83.56 and a 52 week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same period in the prior year, the business earned ($1.97) earnings per share. On average, analysts expect that SAGE Therapeutics will post -7.58 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Flinton Capital Management LLC boosted its position in shares of SAGE Therapeutics by 1,900.0% during the 2nd quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 646 shares in the last quarter. US Bancorp DE boosted its position in shares of SAGE Therapeutics by 5,593.3% during the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 839 shares in the last quarter. Creative Planning bought a new stake in shares of SAGE Therapeutics during the 2nd quarter valued at about $210,000. Atria Investments LLC bought a new stake in shares of SAGE Therapeutics during the 2nd quarter valued at about $218,000. Finally, Tiverton Asset Management LLC bought a new stake in shares of SAGE Therapeutics during the 2nd quarter valued at about $229,000.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: How to Use the New Google Finance Tool

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.